SCHEMBL29577481

SCHEMBL29577481

COc1cc(OC)c(F)c(-c2cc3cnc(SC)nc3c(N3CCC(OC)CC3)n2)c1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TTK P33981 4/20 0.38
▸ DCK P27707 3/20 0.34
▸ PIK3CA P42336 1/20 0.34
▸ NEK2 P51955 4/20 0.33
▸ PLK1 P53350 1/20 0.33
▸ NEK1 Q96PY6 1/20 0.33
▸ PDE4B Q07343 3/20 0.33
▸ PDE4A P27815 2/20 0.33
▸ PDE4C Q08493 2/20 0.33
▸ PDE4D Q08499 2/20 0.33
▸ PDE11A Q9HCR9 2/20 0.33
▸ PDE3B Q13370 1/20 0.33
▸ FGFR4 P22455 1/20 0.32
▸ JAK2 O60674 1/20 0.31
▸ JAK1 P23458 1/20 0.31
▸ TYK2 P29597 1/20 0.31
▸ JAK3 P52333 1/20 0.31
▸ NTSR1 P30989 1/20 0.31
▸ GAK O14976 1/20 0.31
▸ FGFR3 P22607 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21240619 1.00 TTK (0.38) TTKDCKPIK3CANEK2PLK1
SCHEMBL20331967 0.94 TTK (0.37) TTKNEK2PDE3B
SCHEMBL29578126 0.94 TTK (0.37) TTKNEK2PDE3B
SCHEMBL20331102 0.90 TTK (0.36) TTKPDE4BPDE4APDE4CPDE4D
SCHEMBL29577636 0.90 TTK (0.36) TTKPDE4BPDE4APDE4CPDE4D
SCHEMBL30442682 0.89 NOS1 (0.36) TTKPDE4BPDE4APDE4CPDE4D
SCHEMBL21240243 0.89 TTK (0.38) TTKNEK2PLK1NEK1PDE4B
SCHEMBL29578389 0.89 TTK (0.38) TTKNEK2PLK1NEK1PDE4B
SCHEMBL21251916 0.87 TTK (0.39) TTKDCKPIK3CANEK2PLK1
SCHEMBL20331765 0.86 PDE4B (0.45) TTKPDE4BPDE4APDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11555036-B2 FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-01-17 — — US disclosed
US-20220348573-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2022-11-03 — — US disclosed
EP-3524603-B1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF ABBISKO THERAPEUTICS CO LTD (CN) 2022-06-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220348573-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF FGFR4, FGFR2, FGFR1 TTK 3915/4885DCK 2960/4885PIK3CA 88/4885
US-11555036-B2 FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof FGFR4, FGFR2, FGFR1 TTK 3818/4885DCK 2880/4885PIK3CA 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback